American Society of Hirudotherapy

Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies

Narrative review with trial rationale and design published in Journal of thrombosis and thrombolysis (2013)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewClinical LiteratureSergie et al. · Journal of thrombosis and thrombolysis, 2013

Abstract

Transcatheter aortic valve replacement (TAVR) is considered an important option in the management of patients with critical aortic valve stenosis that are either inoperable or have a high surgical risk. Despite continued advances in the procedural aspects of TAVR and decreasing complications rates, the risks of major vascular complications and stroke remain significant, which may in turn confer worse clinical outcomes and impact morbidity and mortality. In this review, we outline certain limitations of the currently recommended periprocedural anticoagulation in TAVR, namely unfractionated heparin that is guided by activated clotting times and protamine use if the bleeding risk is high. We will explore the potential for bivalirudin in this setting, which has become a frontrunner in acute coronary syndrome management because of favorable pharmacokinetics and lower bleeding complications. Finally, we will describe an ongoing large multicenter multinational trial that compares intravenous bivalirudin to unfractionated heparin during TAVR procedures using standardized clinical endpoints.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAgedAged, 80 and overAntithrombinsAortic Valve StenosisCardiac CatheterizationClinical Trials as TopicFemaleHeart Valve ProsthesisHirudinsHumansMalePeptide FragmentsRecombinant Proteins

Summary

Outlining limitations of activated clotting time-guided heparin during transcatheter aortic valve replacement, this paper describes the rationale and design of the BRAVO 2/3 multicenter trial comparing intravenous bivalirudin with unfractionated heparin.

Why This Matters for Hirudotherapy

This review outlines limitations of unfractionated heparin for periprocedural anticoagulation during transcatheter aortic valve replacement (TAVR) and explores the potential of bivalirudin as an alternative, describing the design of an ongoing large multicenter multinational trial comparing intravenous bivalirudin to unfractionated heparin during TAVR procedures using standardized clinical endpoints. The article is indexed under the MeSH term "Hirudins," reflecting bivalirudin's pharmacological relationship to hirudin, which provides a tenuous taxonomic link to leech therapy. However, the abstract itself does not discuss leeches, hirudotherapy, or leech-derived compounds at any point. Its only link to leech therapy is the clinical evaluation of a synthetic anticoagulant with a mechanistic lineage to leech-derived thrombin inhibition.

Citation

Reference (Vancouver style)

Sergie Z, Lefèvre T, Van Belle E, Kakoulides S, Baber U, Deliargyris EN, et al. Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies. J Thromb Thrombolysis. 2013;35(4):483-493. doi:10.1007/s11239-013-0890-3. PMID: 23553245

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.